

Ref. No: FOI000702
From: Public
Date: 09/05/2023
Subject: FOI request on intra-vitreous injections or implants

REQUEST

1. How many of the following intra-vitreous injections/implants has your Trust administered in the four-month period from January to April 2023:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis
- Ranibizumab – Ongavia
- Ranibizumab – Byooviz
- Ranibizumab - Ximluci

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2023:

RESPONSE

1. How many of the following intra-vitreous injections/implants has your Trust administered in the four-month period from January to April 2023:

Data CMM DSUM Report: 1st January 2023 - 1st May 2023:

Treatment	No.
Aflibercept	695
Bevacizumab	0
Brolucizumab	14
Dexamethasone	40
Faricimab	22
Fluocinolone acetonide	0
Ranibizumab - Lucentis	681
Ranibizumab – Ongavia	0
Ranibizumab – Byooviz	0
Ranibizumab - Ximluci	0

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2023:

Number of Injections/Implants: January – April 2023

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	511	83	63
Bevacizumab	0	0	0
Brolucizumab	10	0	0
Dexamethasone	0	6	20
Faricimab	18	0	0
Ranibizumab	450	78	111